KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Gains from Investment Securities: 2010-2024

Historic Gains from Investment Securities for Nektar Therapeutics (NKTR) over the last 14 years, with Dec 2024 value amounting to -$7.6 million.

  • Nektar Therapeutics' Gains from Investment Securities rose 19.47% to -$7.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $76,000, marking a year-over-year decrease of 97.14%. This contributed to the annual value of $76,000 for FY2024, which is 97.14% down from last year.
  • Per Nektar Therapeutics' latest filing, its Gains from Investment Securities stood at -$7.6 million for Q4 2024, which was down 469.91% from $2.1 million recorded in Q3 2024.
  • In the past 5 years, Nektar Therapeutics' Gains from Investment Securities registered a high of $6.7 million during Q4 2021, and its lowest value of -$9.5 million during Q4 2023.
  • For the 3-year period, Nektar Therapeutics' Gains from Investment Securities averaged around $504,833, with its median value being $2.3 million (2024).
  • Examining YoY changes over the last 5 years, Nektar Therapeutics' Gains from Investment Securities showed a top increase of 771.70% in 2023 and a maximum decrease of 420.95% in 2023.
  • Nektar Therapeutics' Gains from Investment Securities (Quarterly) stood at $2.1 million in 2020, then plummeted by 209.94% to $6.7 million in 2021, then plummeted by 56.13% to $3.0 million in 2022, then tumbled by 420.95% to -$9.5 million in 2023, then increased by 19.47% to -$7.6 million in 2024.
  • Its last three reported values are -$7.6 million in Q4 2024, $2.1 million for Q3 2024, and $2.6 million during Q2 2024.